臓腺がん患者のトランスクリプトミックの分析は,KRAS媒介によるPPAR経路の変化を明らかにした
Giuseppe Defazio1, Federico Scolari1, Sara Fancelli2
1Department of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, Florence, Italy.
Frontiers in oncology
|August 27, 2025
まとめ
臓がん (PC) の生存率は低下しており,その一部はKRAS変異による. この研究では,KRAS変異PCにおけるペロキシソーム増殖器活性化受容体 (PPAR) 経路の障害が発見され,新たな治療標的が示唆された.
科学分野:
- 腫瘍学
- 分子生物学
- 生物化学
背景:
- 臓がん (PC) の死亡率は高く,治療の選択肢は限られている.
- KRAS変異はPCにおいて一般的であり 腫瘍の攻撃的行動を引き起こします
- 有効なKRAS変異阻害剤は存在しない.
研究 の 目的:
- 臓がんにおけるペロキシソーム増殖剤活性化受容体 (PPAR) 信号伝達経路の役割を調査する.
- PCにおけるPPAR経路不調に対するKRAS変異の影響を分析する.
- KRAS変異したPCの潜在的治療標的を特定する.
主な方法:
- 癌ゲノムアトラス (TCGA) データセットからのRNAシーケンシングデータの分析.
- 腫瘍と正常な臓組織の比較,KRAS変異状態によって層分化.
- RT-qPCRを用いた主要な遺伝子発現変化の検証
主要な成果:
- PCでは,PPARシグナル伝達経路の有意な失調が観察されました.
- KRAS変異は,PPAR経路遺伝子のさらなるダウンレギュレーションと関連していました.
- CD36,FABP4,PLIN1,PLIN4,SCD5,ACSLを含む重要な遺伝子は,腫瘍組織,特にKRAS変異のサンプルでダウンレギュレーションされた.
結論:
- PPAR経路の障害は,KRAS変異性臓がんの重要な特徴です.
- PPAR経路をターゲットにすることで,PCに対する新しい治療戦略が提供される可能性があります.
- PC治療の成果を改善するために,PPAR経路の調節に関するさらなる研究が必要である.
関連する概念動画
The Ras Gene
6.4K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
Ras is a...
6.4K
mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K
PI3K/mTOR/AKT Signaling Pathway
3.9K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.9K
Tumor Progression
6.5K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.5K


